Company Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
18.64 USD -1.48% Intraday chart for Myriad Genetics, Inc. -8.00% -2.61%

Business Summary

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.

Number of employees: 2,700

Sales per Business

USD in Million2022Weight2023Weight Delta
Hereditary Cancers
43.5 %
306 45.0 % 328 43.5 % +7.30%
Prenatal
20.1 %
116 17.2 % 151 20.1 % +29.98%
Pharmacogenomics
18.4 %
128 18.8 % 139 18.4 % +8.54%
Tumor Profiling
18.0 %
129 19.0 % 136 18.0 % +5.44%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
89.2 %
592 87.2 % 672 89.2 % +13.56%
Rest of World
10.8 %
87 12.8 % 82 10.8 % -6.21%

Managers

Managers TitleAgeSince
Chief Executive Officer 61 20-08-12
Director of Finance/CFO 49 Jan. 28
Chief Tech/Sci/R&D Officer 44 14-03-31
Chief Tech/Sci/R&D Officer - 20-02-29
Chief Tech/Sci/R&D Officer 38 18-07-31
Chief Operating Officer 52 Dec. 10
Public Communications Contact - 22-12-18
Investor Relations Contact - 22-07-31
Corporate Officer/Principal - 23-01-02
Comptroller/Controller/Auditor 43 20-06-30

Members of the board

Members of the board TitleAgeSince
Chairman 65 09-09-15
Director/Board Member 63 22-10-30
Director/Board Member 65 20-05-26
Chief Executive Officer 61 20-08-12
Director/Board Member 71 19-09-24
Director/Board Member 64 19-09-24
Director/Board Member 69 10-06-09
Director/Board Member 50 20-07-20
Director/Board Member 53 20-09-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 89,874,886 88,067,580 ( 97.99 %) 0 97.99 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
15.54 %
13,969,989 15.54 % 298 M $
Vanguard Fiduciary Trust Co.
11.08 %
9,954,233 11.08 % 212 M $
Camber Capital Management LP
8.495 %
7,635,000 8.495 % 163 M $
Wellington Management Co. LLP
8.033 %
7,219,706 8.033 % 154 M $
Glenview Capital Management LLC
5.879 %
5,283,982 5.879 % 113 M $
4,700,631 5.230 % 100 M $
Millennium Management LLC
4.742 %
4,262,021 4.742 % 91 M $
EARNEST Partners LLC
4.355 %
3,913,913 4.355 % 83 M $
Millennium Management LLC
3.851 %
3,461,337 3.851 % 74 M $
U.S. Trust Company of Delaware
3.322 %
2,985,897 3.322 % 64 M $

Company contact information

Myriad Genetics, Inc.

322 North 2200 West

84116, Salt Lake City

+801 584 3600

http://www.myriad.com
address Myriad Genetics, Inc.(MYGN)
  1. Stock Market
  2. Equities
  3. MYGN Stock
  4. Company Myriad Genetics, Inc.